{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:43:15Z","timestamp":1772923395747,"version":"3.50.1"},"reference-count":21,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrheumatologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORJ"],"published-print":{"date-parts":[[2018,8,31]]},"abstract":"\n Background:<\/jats:title>\n Tocilizumab is increasingly used in the treatment of large vessel vasculitis with recent approval for giant cell arteritis.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n To determine the efficacy and safety of tocilizumab in large vessel vasculitis in a real-life setting using different routes of administration.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Retrospective analysis of consecutive patients at a tertiary rheumatology department who received tocilizumab for large vessel vasculitis.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n A total of 11 patients were treated with tocilizumab (8 giant cell arteritis, 2 large vessel vasculitis associated with rheumatoid arthritis, 1 Takayasu arteritis) after a median of 2 other steroid-sparing agents (range 1-4). Of these, 9 received tocilizumab as salvage therapy for active vasculitis and 2 due to the toxicity of their former steroid-sparing medication. After a mean follow-up of 23 months 7 patients were in remission as to vasculitis under a mean prednisolone dose of 1.7 \u00b1 1.5 mg; one patient relapsed after long term remission having discontinued tocilizumab for elective surgery; one patient stopped tocilizumab after attributable infectious complications, and two patients died: one due to complications of vascular surgery, probably not attributable to tocilizumab; and the other due to sepsis secondary to sigmoiditis. Only 3 relapses occurred under continuous tocilizumab treatment. In all these 3 cases, renewed remission could be achieved by switching from subcutaneous (162 mg qw) to intravenous tocilizumab (8mg\/kg q4w).<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Tocilizumab is efficacious in patients with large vessel vasculitis in a real-life situation. Safety appears to be acceptable, but infectious complications have to be considered. Intravenous tocilizumab may be used in patients who relapse under subcutaneous application.<\/jats:p>\n <\/jats:sec>","DOI":"10.2174\/1874312901812010152","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T06:06:16Z","timestamp":1536041176000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tocilizumab in Large Vessel Vasculitis \u2013 Different Routes of Administration"],"prefix":"10.2174","volume":"12","author":[{"given":"Marc","family":"Schmalzing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottar","family":"Gadeholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva C","family":"Schwaneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1874312901610010101","volume":"10","author":"Ernst D.","year":"2016","unstructured":"Ernst D, Bearlecken N, Ernst Schmidt R, Witte T. \n Two subsets of large vessel vasculitis characterized by the absence or presence of spondyloarthritis or its associated diseases. \n Open Rheumatol J \n 2016; \n 10\n : 101-8.","journal-title":"Open Rheumatol. J."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","volume":"55","author":"Labarca C.","year":"2016","unstructured":"Labarca C, Koster MJ, Crowson CS, et al. \n Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: A retrospective cohort study. \n Rheumatology (Oxford) \n 2016; \n 55\n (2)\n : 347-56.","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"Mukhtyar C.","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, et al. \n EULAR recommendations for the management of large vessel vasculitis. \n Ann Rheum Dis \n 2009; \n 68\n (3)\n : 318-23.","journal-title":"Ann. Rheum. Dis."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"Mihara M.","year":"2005","unstructured":"Mihara M, Kasutani K, Okazaki M, et al. \n Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. \n Int Immunopharmacol \n 2005; \n 5\n (12)\n : 1731-40.","journal-title":"Int. Immunopharmacol."},{"key":"ref5","first-page":"w13156","volume":"141","author":"Seitz M.","year":"2011","unstructured":"Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. \n Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. \n Swiss Med Wkly \n 2011; \n 141\n : w13156.","journal-title":"Swiss Med. Wkly."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","volume":"44","author":"Loricera J.","year":"2015","unstructured":"Loricera J, Blanco R, Hern\u00e1ndez JL, et al. \n Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. \n Semin Arthritis Rheum \n 2015; \n 44\n (6)\n : 717-23.","journal-title":"Semin. Arthritis Rheum."},{"key":"ref7","first-page":"S76","volume":"32","author":"Oliveira F.","year":"2014","unstructured":"Oliveira F, Butendieck RR, Ginsburg WW, Parikh K, Abril A. \n Tocilizumab, an effective treatment for relapsing giant cell arteritis. \n Clin Exp Rheumatol \n 2014; \n 32\n (3)\n (Suppl. 82)\n : S76-8.","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/ard.2010.149351","volume":"70","author":"Beyer C.","year":"2011","unstructured":"Beyer C, Axmann R, Sahinbegovic E, et al. \n Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. \n Ann Rheum Dis \n 2011; \n 70\n (10)\n : 1874-5.","journal-title":"Ann. Rheum. Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/acr.21750","volume":"64","author":"Unizony S.","year":"2012","unstructured":"Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. \n Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. \n Arthritis Care Res (Hoboken) \n 2012; \n 64\n (11)\n : 1720-9.","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.3899\/jrheum.110496","volume":"38","author":"Sciascia S.","year":"2011","unstructured":"Sciascia S, Rossi D, Roccatello D. \n Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. \n J Rheumatol \n 2011; \n 38\n (9)\n : 2080-1.","journal-title":"J. Rheumatol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","volume":"51","author":"Salvarani C.","year":"2012","unstructured":"Salvarani C, Magnani L, Catanoso M, et al. \n Tocilizumab: A novel therapy for patients with large-vessel vasculitis. \n Rheumatology (Oxford) \n 2012; \n 51\n (1)\n : 151-6.","journal-title":"Rheumatology (Oxford)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"bcr0420114135","DOI":"10.1136\/bcr.04.2011.4135","volume":"2011","author":"Christidis D.","year":"2011","unstructured":"Christidis D, Jain S, Das Gupta B. \n Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. \n BMJ Case Rep \n 2011; \n 2011\n : bcr0420114135.","journal-title":"BMJ Case Rep."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3899\/jrheum.151252","volume":"43","author":"R\u00e9gent A.","year":"2016","unstructured":"R\u00e9gent A, Redeker S, Deroux A, et al. \n Tocilizumab in giant cell arteritis: A multicenter retrospective study of 34 patients. \n J Rheumatol \n 2016; \n 43\n (8)\n : 1547-52.","journal-title":"J. Rheumatol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"Villiger P.M.","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, et al. \n Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. \n Lancet \n 2016; \n 387\n (10031)\n : 1921-7.","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"Stone J.H.","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. \n Trial of Tocilizumab in giant-cell arteritis. \n N Engl J Med \n 2017; \n 377\n (4)\n : 317-28.","journal-title":"N. Engl. J. Med."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"Strehl C.","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, et al. \n Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an EULAR task force. \n Ann Rheum Dis \n 2016; \n 75\n (6)\n : 952-7.","journal-title":"Ann. Rheum. Dis."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","volume":"66","author":"Ogata A.","year":"2014","unstructured":"Ogata A, Tanimura K, Sugimoto T, et al. \n Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. \n Arthritis Care Res (Hoboken) \n 2014; \n 66\n (3)\n : 344-54.","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester G.R.","year":"2014","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A, et al. \n A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). \n Ann Rheum Dis \n 2014; \n 73\n (1)\n : 69-74.","journal-title":"Ann. Rheum. Dis."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3109\/14397595.2015.1129692","volume":"26","author":"Iwamoto N.","year":"2016","unstructured":"Iwamoto N, Fukui S, Umeda M, et al. \n Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis. \n Mod Rheumatol \n 2016; \n 26\n (5)\n : 662-6.","journal-title":"Mod. Rheumatol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"Nishimoto N.","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. \n Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. \n Blood \n 2008; \n 112\n (10)\n : 3959-64.","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"Strangfeld A.","year":"2017","unstructured":"Strangfeld A, Richter A, Siegmund B, et al. \n Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. \n Ann Rheum Dis \n 2017; \n 76\n (3)\n : 504-10.","journal-title":"Ann. Rheum. Dis."}],"container-title":["The Open Rheumatology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V12\/TORJ-12-152\/TORJ-12-152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V12\/TORJ-12-152\/TORJ-12-152.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V12\/TORJ-12-152\/TORJ-12-152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T07:32:42Z","timestamp":1555313562000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrheumatologyjournal.com\/VOLUME\/12\/PAGE\/152\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,8,31]]}},"alternative-id":["TORJ-12-152"],"URL":"https:\/\/doi.org\/10.2174\/1874312901812010152","relation":{},"ISSN":["1874-3129"],"issn-type":[{"value":"1874-3129","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-5-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-6-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-7-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}